Follow us on Twitter
This page is updated frequently with new Immune Diseases-related patent applications. Subscribe to the Immune Diseases RSS feed to automatically get the update: related Immune RSS feeds. RSS updates for this page: Immune Diseases RSS
|| List of recent Immune Diseases-related patents
| Sirt 1 activator including syringaresinol|
The present invention relates to a compound of formula 1, and an sirt 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the sirt 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases..
| Method for the controlled intracellular delivery of nucleic acids|
The present invention relates to a method for the controlled intracellular delivery of nucleic acid molecules into one or more target cells, in particular tumor cells, the method comprising: providing a polymeric complex formed between one or more nucleic acid molecules to be delivered and one or more cationic carrier molecules, wherein at least a part of the one or more carrier molecules in the polymeric complex are covalently attached to hydroxyalkyl starch, and wherein the hydroxyalkyl starch is shielding the polymeric complex; allowing the shielded polymeric complex to get into contact with the one or more target cells; deshielding the polymeric complex by removing the hydroxyalkyl starch; and allowing the deshielded polymeric complex to internalize into the one or more target cells. Removal of the hydroxyalkyl starch can be accomplished enzymatically by exposing the polymeric complex to amylase.
| Therapeutic compounds|
The invention provides compounds of formula (i) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (i), processes for preparing compounds of formula (i), intermediates useful for preparing compounds of formula (i) and therapeutic methods for treating cancer or treating autoimmune diseases or preventing transplant rejection using compounds of formula (i)..
| Azathioprine oral suspensions and methods of use|
Compositions of azathioprine oral suspensions are disclosed. Disclosed azathioprine oral suspensions may be used to administer azathioprine to subjects such as children and geriatric patients that may have difficulty in swallowing solid dosage forms.
| Novel compounds useful for the treatment of metabolic and inflammatory diseases|
These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative diseases.. .
| Modified epitopes for boosting cd4+ t-cell responses|
The present invention relates to immunogenic peptides comprising a t-cell epitope. Said peptides are modified such that cd4+ t-cell responses are obtainable that are much stronger than the cd4+ t-cell responses obtained with the same peptides not comprising said modification.
| Methods for the treatment or prevention of systemic sclerosis|
The invention is in the field of molecular immunology, more in particular, in the field of the prevention or treatment of autoimmune diseases, more in particular, systemic sclerosis or scleroderma. The invention is based on the observation that ssc patients have an elevated plasma level of cxcl4.
| Preventive and/or ameliorative agent for diseases, stamina enhancement agent, anti-fatigue agent, and pharmaceutical and food and drink using them|
A purple non-sulfur bacteria useful in preventing and/or ameliorating at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases and having high safety is provided. A preventive and/or ameliorative agent is for at least one disease selected from the group consisting of inflammatory diseases, allergic diseases, and autoimmune diseases and includes at least one of a purple non-sulfur bacteria and a culture material obtained by culturing the purple non-sulfur bacteria.
|Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor|
Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
|Method of making monomethyl fumarate|
Methods of making monomethyl fumarate, which can then also be used in methods of making prodrugs of monomethyl fumarate, are disclosed. Monomethyl fumarate and prodrugs of monomethyl fumarate are useful for treating neurodegenerative, inflammatory, and autoimmune diseases including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis..
|Triazolopyridine derivatives as a tyrosine kinase inhibitor|
Provided is a novel triazolopyridine derivative having irreversible tyrosine kinase inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers or tumors.. .
|Antispasmodic 1,2-diols and 1,2,3-triols|
The present invention is directed to pharmaceutical compositions comprising antispasmodic c4-c8aliphatic-1,2-diols and c4-c8aliphatic-1,2,3-triols and their use to relieve the spasms associated with pain. These agents may be administered topically or orally and may be combined with anti-inflammatory agents such as a non-steroidal anti-inflammatory drug or a corticosteroid.
|Method for increasing specificity of diagnostic tests for autoimmune diseases|
Provided is a method for increasing the specificity of an antibody-based test to help in the diagnosis of autoimmune diseases by contacting a subject's sample with a blocking antigen prior interfering antibody present in the sample. More specifically, a method for increasing specificity of an antibody-based autoimmune disease assay comprising the steps of providing a sample from a subject, contacting the sample with a dfs70 derived antigen, reacting the sample with an autoimmune disease target and detecting antibodies to the autoimmune disease target is disclosed..
|Core-shell particle formulation for delivering multiple therapeutic agents|
A core-shell particle formulation for delivering multiple therapeutic agents is disclosed. More particularly, core-shell particle formulation configured to independently release therapeutic agents from the core and the shell.
|Nanocell drug delivery system|
Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent.
|Oxidized cardiolipin as a novel pro-inflammatory factor|
Low levels of antibodies reactive with oxidised cardiolipin (oxcl) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxcl.
|Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof|
The present invention relates to processes and intermediates useful in the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of formula (ia) and salts thereof, an s1p1 receptor modulator that is useful in the treatment of s1p1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).. .
|Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine h4 receptor|
Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as h4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.. .
|Novel urea and thiourea derivatives|
The present application discloses compounds of formula (i) wherein x is ═o, ═s, ═nh, ═noh and ═no-me; a is —c(═o)—, —s(═o)2—, —c(═s)— and p(═o)(r5)—; b is, —o—, —(ch2)3-6—, and o—(ch2)2-5—; d is, —o—, —cr7r8— and —nr9; m is 0-12, n is 0-12, m+n is 1-20; p is 0-4; r1 is opt.sub. Heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof.
|Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases|
The invention provides modulators for the orphan nuclear receptor rorγ and methods for treating rorγ mediated diseases by administrating these novel rorγ modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo carboxamide compounds of formula (1) and the enantiomers, diastereomers, n-oxides, tautomers, solvates and pharmaceutically acceptable salts thereof..
|Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent|
Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between sema3a and a neuropilin-1/plexin-a1 heteroreceptor. The substance includes, for example, a sema3a neutralizing antibody, a neuropilin-1 neutralizing antibody, or a soluble neuropilin-1 or derivative thereof.
|Novel phytosphingosine derivatives, and composition comprising same for preventing and treating inflammatory skin diseases, autoimmune diseases, and hyperkeratosis diseases|
A phytosphingosine derivative of chemical formula ia or ib, and a composition comprising the phytosphingosine derivative for preventing and treating inflammatory skin diseases, autoimmune diseases, and hyperkeratotic diseases. The phytosphingosine derivatives of the present disclosure are involved with transcription factors related to inflammation, autoimmune diseases and hyperkeratotic diseases, the expression and the generation of inflammatory mediators, signal transduction mechanisms, and the expression and the activity of relevant enzymes and the like..
|Mutant hsp70i to prevent autoimmune disease|
A vaccine and method of treatment suitable for treating autoimmune diseases, such as vitiligo, by using variant peptides representing a sequence of amino acids found in heat shock protein 70. The vaccine includes a peptide derived from inducible heat shock protein 70 and a plasmid containing a full inducible heat shock protein 70 dna sequence encoding the peptide..
|Use of pdl1 expressing cells to convert t cells into regulatory t cells|
The present invention provides methods and compositions for converting a t cell into a cell that exhibits at least one regulatory t cell phenotype. The converted t cell is generated by contacting a t cell with a cell that is modified to comprise an agent capable of activating pd1 signaling in a t cell.
|Human-derived bacteria that induce proliferation or accumulation of regulatory t cells|
Species of human-derived bacteria belonging to the clostridia class have been shown to induce accumulation of regulatory t cells (treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases..
|Inhibitors of bruton's tyrosine kinase|
Disclosed herein are pyrazolo[3,4-d]pyrimidines that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
|Crystalline forms of a bruton's tyrosine kinase inhibitor|
Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
|Silicon-containing fumaric acid esters|
The present invention is directed to silicon-containing fumaric acid esters of the formulae i-iv. The silicon-containing fumaric acid esters of formulae i-iv are useful in transplantation medicine and for the treatment of autoimmune diseases and autoimmune-related diseases.
|Utility of insulin-like 6 (insl6) for the treatment of autoimmune diseases|
The present invention is directed to compositions and methods to treat an autoimmune disease in a subject, comprising an insulin-like 6 (insl6) agent, such as an insl6 polypeptide or variant or fragment thereof, or a nucleic acid encoding insl6 poly peptide or variant or fragment thereof. Aspects of the present invention relate to use of insl6 agents to reduce t-regulatory (treg) cells in the subject and to reduce pro-inflammatory cytokines in a subject with an autoimmune disease such as a muscle autoimmune disease.
|Immunoglobulin constant region fc receptor binding agents|
Ivig replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function.
|Small molecule inhibitors of stat3 with anti-tumor activity|
The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, nsc 74859 (s31-201), nsc 42067, nsc 59263, nsc 75912, nsc 11421, nsc 91529, nsc 263435, and pharmaceutically acceptable salts and analogs of the foregoing.
|Inhibitors of c-fms kinase|
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
|Her2/neu-specific antibodies and methods of using same|
This invention relates to antibodies that specifically bind her2/neu, and particularly chimeric 4d5 antibodies to her2/neu, which have reduced glycosylation as compared to known 4d5 antibodies. The invention also relates to methods of using the 4d5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
|Mesenchymal stem cells and uses therefor|
Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.. .
|Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities|
Which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-fms (csf-1r), c-kit, and/or pdgfr kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-fms, c-kit, or pdgfr kinases..
|Materials and methods for modulating immune responses|
The present invention provides nanoparticle-coupled tolerogenic treg cell therapy for treatment of immune and/or autoimmune disorders. In certain specific embodiments, the present invention can be used in the prevention and/or treatment of autoimmune diseases including, but not limited to, type 1 diabetes, lupus erythematosus (sle), multiple sclerosis (ms), inflammatory bowel disease (ibd), rheumatoid arthritis, oophoritis, and autoimmune pathology associated with graft versus host disease (gvhd) following hematopoietic stem cell transplantation..
|Bi-specific antibodies for medical use|
A bispecific antibody format devoid of an active fc moiety comprising a monovalent binding site for a death receptor and at least one binding site for a cell surface antigen expressed on b-cells, for use in the treatment or prevention of b cell mediated autoimmune diseases.. .
|Il-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment|
A novel approach to discover new drugs against ms and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (il-12), the p40 monomer (p40), the p40 homodimer (p402), and the il-23.
Popular terms: [SEARCH]
Immune Diseases topics: Immune Diseases, Autoimmune, Immune Disease, Autoimmune Disease, Autoimmune Diseases, Immune Disorder, Rheumatoid Arthritis, Antibodies, Antagonist, Nucleotide, Proliferative, Infectious, Infectious Disease, Infectious Diseases, Type 1 Diabetes
Follow us on Twitter
This listing is a sample listing of patent applications related to Immune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.